Cargando…
Cellular Adaptation to VEGF-Targeted Antiangiogenic Therapy Induces Evasive Resistance by Overproduction of Alternative Endothelial Cell Growth Factors in Renal Cell Carcinoma()()
Vascular endothelial growth factor (VEGF)–targeted antiangiogenic therapy significantly inhibits the growth of clear cell renal cell carcinoma (RCC). Eventually, therapy resistance develops in even the most responsive cases, but the mechanisms of resistance remain unclear. Herein, we developed two t...
Autores principales: | Han, Kyung Seok, Raven, Peter A., Frees, Sebastian, Gust, Kilian, Fazli, Ladan, Ettinger, Susan, Hong, Sung Joon, Kollmannsberger, Cristian, Gleave, Martin E., So, Alan I. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Neoplasia Press
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4681895/ https://www.ncbi.nlm.nih.gov/pubmed/26678908 http://dx.doi.org/10.1016/j.neo.2015.11.001 |
Ejemplares similares
-
Inhibition of endoplasmic reticulum chaperone protein glucose-regulated protein 78 potentiates anti-angiogenic therapy in renal cell carcinoma through inactivation of the PERK/eIF2α pathway
por: Han, Kyung Seok, et al.
Publicado: (2015) -
Antiangiogenic VEGF Isoform in Inflammatory Myopathies
por: Volpi, Nila, et al.
Publicado: (2013) -
The role of netrin-1 in metastatic renal cell carcinoma treated with sunitinib
por: Frees, Sebastian, et al.
Publicado: (2018) -
VEGF(165)b, an antiangiogenic VEGF-A isoform, binds and inhibits bevacizumab treatment in experimental colorectal carcinoma: balance of pro- and antiangiogenic VEGF-A isoforms has implications for therapy
por: Varey, A H R, et al.
Publicado: (2008) -
Biomarkers of evasive resistance predict disease progression in cancer patients treated with antiangiogenic therapies
por: Pircher, Andreas, et al.
Publicado: (2016)